-
If you purchased shares of Cynapsus Therapeutics Inc (NASDAQ:CYNA) and currently hold any of those NASDAQ:CYNA shares, you have certain options and you should contact the Shareholders Foundation, Inc.
-
To have your information reviewed for options and to receive notifications about this investigation, please send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.
Investigation Overview
September 12, 2016 (Shareholders Foundation) - An investigation on behalf of investors, who currently hold shares of Cynapsus Therapeutics Inc (NASDAQ:CYNA), was announced concerning whether the takeover of Cynapsus Therapeutics Inc by Sunovion Pharmaceuticals Inc for $40.50 per share is unfair to NASDAQ:CYNA stockholders.
The investigation by a law firm concerns whether certain officers and directors of Cynapsus Therapeutics Inc breached their fiduciary duties owed to NASDAQ:CYNA investors in connection with the proposed acquisition.
On August 31, 2016, Sunovion Pharmaceuticals Inc. (Sunovion) and Cynapsus Therapeutics Inc (NASDAQ:CYNA) (TSX: CTH) announced that the companies have signed an agreement under which Sunovion Pharmaceuticals Inc. will acquire Cynapsus for US$40.50 per share in cash.
However, the investigation concerns whether the offer is unfair to NASDAQ:CYNA stockholders. More specifically, the investigation concerns whether the Cynapsus Therapeutics Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.
